199 related articles for article (PubMed ID: 28481787)
1. Evaluation of Practical Interpretation Hurdles in 68Ga-PSMA PET/CT in 55 Patients: Physiological Tracer Distribution and Incidental Tracer Uptake.
Kirchner J; Schaarschmidt BM; Sawicki LM; Heusch P; Hautzel H; Ermert J; Rabenalt R; Antoch G; Buchbender C
Clin Nucl Med; 2017 Jul; 42(7):e322-e327. PubMed ID: 28481787
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
4. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with
Kalshetty A; Menon B; Rakshit S; Bhattacharjee A; Basu S
J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223
[TBL] [Abstract][Full Text] [Related]
6.
Rischpler C; Beck TI; Okamoto S; Schlitter AM; Knorr K; Schwaiger M; Gschwend J; Maurer T; Meyer PT; Eiber M
J Nucl Med; 2018 Sep; 59(9):1406-1411. PubMed ID: 29371407
[TBL] [Abstract][Full Text] [Related]
7. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
[TBL] [Abstract][Full Text] [Related]
8. Quantitative Test-Retest Measurement of
Pollard JH; Raman C; Zakharia Y; Tracy CR; Nepple KG; Ginader T; Breheny P; Sunderland JJ
J Nucl Med; 2020 Aug; 61(8):1145-1152. PubMed ID: 31806776
[TBL] [Abstract][Full Text] [Related]
9. Early dynamic imaging in
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; Warwitz B; Scarpa L; Roig LG; Kendler D; von Guggenberg E; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):765-775. PubMed ID: 27900519
[TBL] [Abstract][Full Text] [Related]
10. Retrospective correlation of
Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
[TBL] [Abstract][Full Text] [Related]
11. Reproducibility of standardized uptake values of same-day randomized
Ringheim A; Campos Neto GC; Martins KM; Vitor T; da Cunha ML; Baroni RH
Ann Nucl Med; 2018 Oct; 32(8):523-531. PubMed ID: 29982989
[TBL] [Abstract][Full Text] [Related]
12. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
14. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?
Demirci E; Kabasakal L; Şahin OE; Akgün E; Gültekin MH; Doğanca T; Tuna MB; Öbek C; Kiliç M; Esen T; Kural AR
Nucl Med Commun; 2019 Jan; 40(1):86-91. PubMed ID: 30395048
[TBL] [Abstract][Full Text] [Related]
15. Factors Predicting Metastatic Disease in
Chiu LW; Lawhn-Heath C; Behr SC; Juarez R; Perez PM; Lobach I; Bucknor MD; Hope TA; Flavell RR
J Nucl Med; 2020 Dec; 61(12):1779-1785. PubMed ID: 32303599
[TBL] [Abstract][Full Text] [Related]
16. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer.
Verburg FA; Pfister D; Drude NI; Mottaghy FM; Behrendt FF
Nuklearmedizin; 2017; 56(6):225-232. PubMed ID: 29044297
[TBL] [Abstract][Full Text] [Related]
17. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical Validation of PSMA Expression Measured by
Woythal N; Arsenic R; Kempkensteffen C; Miller K; Janssen JC; Huang K; Makowski MR; Brenner W; Prasad V
J Nucl Med; 2018 Feb; 59(2):238-243. PubMed ID: 28775203
[No Abstract] [Full Text] [Related]
19.
Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
[TBL] [Abstract][Full Text] [Related]
20.
Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]